{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T13:20:11Z","timestamp":1790083211007,"version":"4.0.1"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T00:00:00Z","timestamp":1754092800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004107","name":"Sabin Vaccine Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004107","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000016","name":"U.S. Department of Health and Human Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012399","name":"Biomedical Advanced Research and Development Authority","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016820","name":"Vaccine Research Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016820","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100021704","name":"Administration for Strategic Preparedness and Response","doi-asserted-by":"publisher","award":["75A50119C00055"],"award-info":[{"award-number":["75A50119C00055"]}],"id":[{"id":"10.13039\/100021704","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eBioMedicine"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.ebiom.2025.105889","type":"journal-article","created":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T22:14:23Z","timestamp":1756937663000},"page":"105889","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Safety, tolerability, immunogenicity, and plasmapheresis-based antibody collection in a phase 1b open label trial of two investigational monovalent chimpanzee adenoviral vectored filovirus vaccines, cAd3-Sudan and cAd3-Marburg, in healthy adults"],"prefix":"10.1016","volume":"119","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1806-4892","authenticated-orcid":false,"given":"Ekaterina","family":"Vert-Wong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E.","family":"Stevenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxana","family":"Rustomjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney L.","family":"Finch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jocelyn","family":"Jakubik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8764-4937","authenticated-orcid":false,"given":"Thomas H.","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ebiom.2025.105889_bib1","article-title":"Filovirus disease outbreaks: a chronological overview","volume":"10","author":"Languon","year":"2019","journal-title":"Virology (Auckl)"},{"key":"10.1016\/j.ebiom.2025.105889_bib2","series-title":"Disease Outbreak News: Sudan Virus Disease - Uganda","year":"2025"},{"key":"10.1016\/j.ebiom.2025.105889_bib3","series-title":"Ebola. Outbreak History","year":"2024"},{"key":"10.1016\/j.ebiom.2025.105889_bib4","series-title":"Marburg Virus Disease. History of Marburg Disease Outbreaks","year":"2025"},{"key":"10.1016\/j.ebiom.2025.105889_bib5","series-title":"Disease Outbreak News. Marburg Virus Disease - Equatorial Guinea","year":"2023"},{"key":"10.1016\/j.ebiom.2025.105889_bib6","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.jiph.2020.03.014","article-title":"Ebola outbreak in West Africa, 2014 \u2013 2016: epidemic timeline, differential diagnoses, determining factors, and lessons for future response","volume":"13","author":"Kamorudeen","year":"2020","journal-title":"J Infect Public Health"},{"key":"10.1016\/j.ebiom.2025.105889_bib7","doi-asserted-by":"crossref","first-page":"S446","DOI":"10.1093\/infdis\/jiad362","article-title":"Filoviruses: scientific gaps and prototype pathogen recommendation","volume":"228","author":"Dupuy","year":"2023","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ebiom.2025.105889_bib8","series-title":"The Filoviruses","year":"2025"},{"key":"10.1016\/j.ebiom.2025.105889_bib9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1010078","article-title":"Current state of Ebola virus vaccines: a snapshot","volume":"17","author":"Woolsey","year":"2021","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.ebiom.2025.105889_bib10","series-title":"Ebola. Ebola Disease Basics","year":"2024"},{"key":"10.1016\/j.ebiom.2025.105889_bib11","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1016\/S1473-3099(23)00344-4","article-title":"Safety, tolerability, and immunogenicity of the Ebola Sudan chimpanzee adenovirus vector vaccine (cAd3-EBO S) in healthy Ugandan adults: a phase 1, open-label, dose-escalation clinical trial","volume":"23","author":"Mwesigwa","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ebiom.2025.105889_bib12","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S0140-6736(22)02400-X","article-title":"Safety, tolerability, and immunogenicity of the chimpanzee adenovirus type 3-vectored Marburg virus (cAd3-Marburg) vaccine in healthy adults in the USA: a first-in-human, phase 1, open-label, dose-escalation trial","volume":"401","author":"Hamer","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ebiom.2025.105889_bib13","article-title":"A single-shot ChAd3 vaccine provides protection from intramuscular and aerosol Sudan virus exposure","author":"Honko","year":"2024","journal-title":"bioRxiv"},{"key":"10.1016\/j.ebiom.2025.105889_bib14","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abq6364","article-title":"A single-shot ChAd3-MARV vaccine confers rapid and durable protection against Marburg virus in nonhuman primates","volume":"14","author":"Hunegnaw","year":"2022","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ebiom.2025.105889_bib15","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.3390\/vaccines10111935","article-title":"Single-shot ChAd3-MARV vaccine in modified formulation buffer shows 100% protection of NHPs","volume":"10","author":"Finch","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.ebiom.2025.105889_bib16","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.4161\/hv.29594","article-title":"Pre-existing immunity against Ad vectors","volume":"10","author":"Fausther-Bovendo","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.ebiom.2025.105889_bib17","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1080\/14760584.2017.1394842","article-title":"Chimpanzee adenoviral vectors as vaccines \u2013 challenges to move the technology into the fast lane","volume":"16","author":"Vitelli","year":"2017","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.ebiom.2025.105889_bib18","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"310","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.ebiom.2025.105889_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0215457","article-title":"Development, qualification, and validation of the Filovirus Animal Nonclinical Group anti-Ebola virus glycoprotein immunoglobulin G enzyme-linked immunosorbent assay for human serum samples","volume":"14","author":"Rudge","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.ebiom.2025.105889_bib20","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1038\/mt.2009.130","article-title":"New insights on adenovirus as vaccine vectors","volume":"17","author":"Lasaro","year":"2009","journal-title":"Mol Ther"},{"key":"10.1016\/j.ebiom.2025.105889_bib21","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1056\/NEJMoa1410863","article-title":"Chimpanzee adenovirus vector Ebola vaccine","volume":"376","author":"Ledgerwood","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ebiom.2025.105889_bib22","doi-asserted-by":"crossref","first-page":"8133","DOI":"10.1038\/s41467-024-51021-5","article-title":"Longitudinal proteome-wide antibody profiling in Marburg virus survivors identifies wing domain immunogen for vaccine design","volume":"15","author":"Khurana","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.ebiom.2025.105889_bib23","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1084\/jem.20170161","article-title":"Marburg virus survivor immune responses are Th1 skewed with limited neutralizing antibody responses","volume":"214","author":"Stonier","year":"2017","journal-title":"J Exp Med"},{"key":"10.1016\/j.ebiom.2025.105889_bib24","article-title":"Bridging animal and human data in pursuit of vaccine licensure","volume":"10","author":"Finch","year":"2022","journal-title":"Vaccines (Basel)"}],"container-title":["eBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396425003330?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396425003330?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T17:40:43Z","timestamp":1772905243000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396425003330"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":24,"alternative-id":["S2352396425003330"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2025.105889","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety, tolerability, immunogenicity, and plasmapheresis-based antibody collection in a phase 1b open label trial of two investigational monovalent chimpanzee adenoviral vectored filovirus vaccines, cAd3-Sudan and cAd3-Marburg, in healthy adults","name":"articletitle","label":"Article Title"},{"value":"eBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2025.105889","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105889"}}